Insulet Corp

NASDAQ:PODDUnited States

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.

Contact Information

Headquarters

100 Nagog ParkACTON, MA, United States 01720-3440

Phone

978-600-7000

Fax

978-600-0120

Executives

Independent Chairman of the Board

Timothy Scannell

President, Chief Executive Officer, Director

James Hollingshead

Chief Financial Officer, Executive Vice President, Treasurer

Ana Chadwick

Chief Human Resource Officer, Senior Vice President

Dan Manea

Executive Vice President, Chief Product and Customer Experience Officer

Eric Benjamin